Dr. Jennifer B. Dean
Claim this profileJohns Hopkins All Children's Hospital
Studies Hodgkin's Lymphoma
Studies B-Cell Lymphoblastic Leukemia-Lymphoma
12 reported clinical trials
45 drugs studied
Area of expertise
1Hodgkin's Lymphoma
Stage IV
Stage III
Stage I
2B-Cell Lymphoblastic Leukemia-Lymphoma
Affiliated Hospitals
Clinical Trials Jennifer B. Dean is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
More about Jennifer B. Dean
Clinical Trial Related6 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Jennifer B. Dean has experience with
- Cyclophosphamide
- Nivolumab
- Doxorubicin Hydrochloride
- Brentuximab Vedotin
- Vincristine Sulfate
- Radiation Therapy
Breakdown of trials Jennifer B. Dean has run
Hodgkin's Lymphoma
B-Cell Lymphoblastic Leukemia-Lymphoma
Burkitt Lymphoma
Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jennifer B. Dean specialize in?
Jennifer B. Dean focuses on Hodgkin's Lymphoma and B-Cell Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Hodgkin's Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Jennifer B. Dean currently recruiting for clinical trials?
Yes, Jennifer B. Dean is currently recruiting for 7 clinical trials in Saint Petersburg Florida. If you're interested in participating, you should apply.
Are there any treatments that Jennifer B. Dean has studied deeply?
Yes, Jennifer B. Dean has studied treatments such as Cyclophosphamide, Nivolumab, Doxorubicin Hydrochloride.
What is the best way to schedule an appointment with Jennifer B. Dean?
Apply for one of the trials that Jennifer B. Dean is conducting.
What is the office address of Jennifer B. Dean?
The office of Jennifer B. Dean is located at: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida 33701 United States. This is the address for their practice at the Johns Hopkins All Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.